Brief: Cipher Pharmaceuticals Reports Q4 Total Revenue Of $5.9 Mln

Cipher Pharmaceuticals

25/03/2020 22:07

March 25 (Reuters) - Cipher Pharmaceuticals Inc  CPH.TO :
    * CIPHER PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR 2019
FINANCIAL RESULTS
    * CIPHER PHARMACEUTICALS - QTRLY TOTAL REVENUE DECREASED 8%
TO
$5.9 MILLION FROM $6.4 MILLION
    * CIPHER PHARMACEUTICALS - QTRLY EARNINGS PER COMMON SHARE
INCREASED TO $0.10
    * CIPHER PHARMACEUTICALS INC - NOTICE FROM BAUSCH HAS
IMPACTED
TIMING OF STRATEGIC REVIEW PROCESS
    * CIPHER PHARMACEUTICALS INC - AT ONSET OF STRATEGIC REVIEW
BOARD
CONTEMPLATED TWO SCENARIOS FOR CANADIAN COMMERCIAL ASSETS
    * CIPHER PHARMACEUTICALS - FIRST OPTION UNDER REVIEW OPTION,
WAS
TO SELL ASSETS TO A SINGLE BUYER OR MULTIPLE BUYERS
    * CIPHER PHARMACEUTICALS INC - SECOND OPTION WAS TO FIND
MOST
COST-EFFECTIVE MEANS TO DISTRIBUTE CANADIAN COMMERCIAL PRODUCTS
    * CIPHER PHARMACEUTICALS INC - PROGRESS HAD BEEN MADE ON
BOTH
FRONTS PRIOR TO NOTICE FROM BAUSCH
    * CIPHER PHARMACEUTICALS INC - DUE TO LEGAL DISPUTE WITH
BAUSCH,
CO MUST NOW FOCUS FIRST OPTION ON SELLING ASSETS INDIVIDUALLY
    * CIPHER PHARMACEUTICALS INC -EXPECTS DISCUSSIONS WITH
GALEPHAR
REGARDING NEW PRODUCT OPPORTUNITIES IN 2020

Source text for Eikon:  ID:nCNWtPypsa 
Further company coverage:  CPH.TO 

 ((Reuters.Briefs@thomsonreuters.com;))